Article
Outcome improvement of cellular cardiomyoplasty using triple therapy: mesenchymal stem cell+erythropoietin+vascular endothelial growth factor.
European journal of pharmacology - 15 Aug 2013
Tavakoli Fatemeh, Ostad Seyed Nasser, Khori Vahid, Alizadeh Ali Mohammad, Sadeghpour Anita, Darbandi Azar Amir, Haghjoo Majid, Zare Asghar, Nayebpour Mohsen
Abstract excerpt
To improve cellular cardiomyoplasty efficacy after myocardial infarction (MI), we postulated that combining mesenchymal stem cells (MSCs) transplantation with anti-apoptotic and angiogenic effects of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) may provide better prognosis in an infarcted heart 48 rats, underwent left anterior descending artery ligation, were divided into eight groups and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
